Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

The quest for new drugs to prevent osteoporosis-related fractures.

de Villiers TJ.

Climacteric. 2017 Apr;20(2):103-106. doi: 10.1080/13697137.2017.1289659. Epub 2017 Mar 3. Review.

PMID:
28286990
2.

Revised global consensus statement on menopausal hormone therapy.

de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C, Pierroz DD.

Maturitas. 2016 Sep;91:153-5. doi: 10.1016/j.maturitas.2016.06.001. Epub 2016 Jun 16.

PMID:
27389038
3.

Cardiovascular risk assessment in women - an update.

Collins P, Webb CM, de Villiers TJ, Stevenson JC, Panay N, Baber RJ.

Climacteric. 2016 Aug;19(4):329-36. doi: 10.1080/13697137.2016.1198574. Epub 2016 Jun 21. Review.

PMID:
27327421
4.

Revised Global Consensus Statement on Menopausal Hormone Therapy.

de Villiers TJ, Hall JE, Pinkerton JV, Cerdas Pérez S, Rees M, Yang C, Pierroz DD.

Climacteric. 2016 Aug;19(4):313-5. doi: 10.1080/13697137.2016.1196047. Epub 2016 Jun 20. No abstract available.

PMID:
27322027
5.

2016 IMS Recommendations on women's midlife health and menopause hormone therapy.

Baber RJ, Panay N, Fenton A; IMS Writing Group..

Climacteric. 2016 Apr;19(2):109-50. doi: 10.3109/13697137.2015.1129166. Epub 2016 Feb 12.

PMID:
26872610
6.

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.

Bruyniks N, Nappi RE, Castelo-Branco C, de Villiers TJ, Simon J.

Climacteric. 2016;19(1):60-5. doi: 10.3109/13697137.2015.1113517. Epub 2015 Nov 19.

7.

The role of menopausal hormone therapy in the management of osteoporosis.

de Villiers TJ.

Climacteric. 2015;18 Suppl 2:19-21. doi: 10.3109/13697137.2015.1099806. Epub 2015 Oct 16. Review.

PMID:
26474003
8.

A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.

Palacios S, Silverman SL, de Villiers TJ, Levine AB, Goemaere S, Brown JP, De Cicco Nardone F, Williams R, Hines TL, Mirkin S, Chines AA; Bazedoxifene Study Group..

Menopause. 2015 Aug;22(8):806-13. doi: 10.1097/GME.0000000000000419.

PMID:
25668306
9.

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.

Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA.

Climacteric. 2015 Apr;18(2):233-40. doi: 10.3109/13697137.2014.975199. Epub 2014 Dec 16.

10.

8th Pieter van Keep Memorial Lecture. Estrogen and bone: have we completed a full circle?

de Villiers TJ.

Climacteric. 2014 Dec;17 Suppl 2:4-7. doi: 10.3109/13697137.2014.953047. Epub 2014 Sep 22.

PMID:
25242261
11.

South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014.

Guidozzi F, Alperstein A, Bagratee JS, Dalmeyer P, Davey M, de Villiers TJ, Hirschowitz S, Kopenhager T, Moodley SP, Roos P, Shaw A, Shimange O, Smith T, Thomas C, Titus J, van der Spuy Z, van Waart J; Council of the South African Menopause Society..

S Afr Med J. 2014 Jun 19;104(8):537-43. doi: 10.7196/samj.8423.

PMID:
25213840
12.

The safety of osteoporosis medication.

Hough FS, Brown SL, Cassim B, Davey MR, de Lange W, de Villiers TJ, Ellis GC, Lipschitz S, Lukhele M, Pettifor JM; National Osteoporosis Foundation of South Africa..

S Afr Med J. 2014 Apr;104(4):279-82.

PMID:
25118550
13.

Prevention of diseases after menopause.

Lobo RA, Davis SR, De Villiers TJ, Gompel A, Henderson VW, Hodis HN, Lumsden MA, Mack WJ, Shapiro S, Baber RJ.

Climacteric. 2014 Oct;17(5):540-56. doi: 10.3109/13697137.2014.933411. Epub 2014 Jun 27. Review.

PMID:
24969415
14.

Risks and benefits of hormone therapy: has medical dogma now been overturned?

Shapiro S, de Villiers TJ, Pines A, Sturdee DW, Baber RJ, Panay N, Stevenson JC, Mueck AO, Burger HG.

Climacteric. 2014 Jun;17(3):215-22. doi: 10.3109/13697137.2014.905529. Epub 2014 Apr 23.

PMID:
24654673
15.

Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures.

de Villiers TJ.

Climacteric. 2014 Feb;17(1):101. No abstract available.

PMID:
24571030
16.

Cancer-associated bone disease.

Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Glüer CC, Kendler D, Napoli N, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, de Villiers TJ, El Hajj Fuleihan G; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease..

Osteoporos Int. 2013 Dec;24(12):2929-53. doi: 10.1007/s00198-013-2530-3. Epub 2013 Oct 22. Review.

17.

Oncology in midlife and beyond.

Gompel A, Baber RJ, de Villiers TJ, Huang KE, Santen RJ, Shah D, Villaseca P, Shapiro S.

Climacteric. 2013 Oct;16(5):522-35. doi: 10.3109/13697137.2013.823539. Epub 2013 Aug 9. Review.

PMID:
23931571
18.

Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.

Palacios S, de Villiers TJ, Nardone Fde C, Levine AB, Williams R, Hines T, Mirkin S, Chines AA; BZA Study Group..

Maturitas. 2013 Sep;76(1):81-7. doi: 10.1016/j.maturitas.2013.06.008. Epub 2013 Jul 18.

PMID:
23871271
19.

Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health.

de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ, Davis SR, Gompel AA, Henderson VW, Langer R, Lobo RA, Plu-Bureau G, Sturdee DW; International Menopause Society..

Climacteric. 2013 Jun;16(3):316-37. doi: 10.3109/13697137.2013.795683. No abstract available.

PMID:
23672656
20.

Global Consensus Statement on menopausal hormone therapy.

de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M.

Maturitas. 2013 Apr;74(4):391-2. doi: 10.1016/j.maturitas.2013.02.001. No abstract available.

PMID:
23497918

Supplemental Content

Loading ...
Support Center